RAB27A and neoplasm: To evaluate the effect of endogenous TEVs on αPD-L1 antitumor activity, we used Rab27a-deficient MC38 cells (MC38 Rab27a−/−) with impaired TEV secretion (Supplementary Fig. 3h, i) to establish tumor-bearing mice.